Amgen Ventures

Type

CVC

Status

Active

Location

Thousand Oaks, United States

Total investments

110

Average round size

49M

Portfolio companies

72

Rounds per year

5.50

Lead investments

7

Follow on index

0.33

Exits

27

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyAnalyticsInformation TechnologyHealth CareGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

In 2004 was created Amgen Ventures, which is appeared as VC. The main department of described VC is located in the San Francisco. The fund was located in North America if to be more exact in United States.

The fund was created by Leroy Hood, Marvin Caruthers. Besides them, we counted 1 critical employee of this fund in our database.

Among the most popular fund investment industries, there are Health Care, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Alector, TetraLogic Pharmaceuticals, Senti Biosciences. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Amgen Ventures, startups are often financed by Alta Partners, SV Health Investors, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are OVP Venture Partners, HealthCare Ventures, Alta Partners. In the next rounds fund is usually obtained by HealthCare Ventures, Alta Partners, Remeditex Ventures.

This Amgen Ventures works on 1 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from Amgen Ventures is 100-500 millions dollars. Considering the real fund results, this VC is 11 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life Sciences
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
110
Lead investments
7
Exits
27
Rounds per year
5.50
Follow on index
0.33
Investments by industry
  • Biotechnology (98)
  • Health Care (71)
  • Therapeutics (48)
  • Medical (43)
  • Pharmaceutical (17)
  • Show 33 more
Investments by region
  • United States (94)
  • China (1)
  • Canada (3)
  • United Kingdom (4)
  • Ireland (2)
  • Show 3 more
Peak activity year
2022
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
53M
Group Appearance index
0.98
Avg. company exit year
8
Avg. multiplicator
4.46
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
DJS Antibodies 22 Dec 2020 Biotechnology, Health Care Seed 8M England, Oxford, United Kingdom
Kernal Biologics 07 Jul 2022 Biotechnology, Pharmaceutical, Therapeutics Early Stage Venture 25M United States, Massachusetts, Cambridge
SingOn 25 Jan 2013 Music, Media and Entertainment, Music Streaming Seed 590K North Ostrobothnia, Oulu, Finland

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.